Avalon GloboCare Corp. (AVCO) has seen a jump of 6.28% in the aftermarket. However, the last trading session closed at $0.9221 with a decline of 5.23%.
US and International Patent Application – Worth it?
On 14th October 2021, AVCO reported that it has effectively co-developed a unique platform of S-layer coated emulsome technology (SLET). Emulsomes have an internal lipoidal area covered by phospholipid multilayers, making them a vesicular nano-carrier structure. When packed with bioactive substances (such as weakly water-soluble medicines and genetic materials. This nano-formulation was also created to be non-toxic and safe.
What are AVCO’s reviews on it?
AVCO is ecstatic to share this innovative SLET platform, which the company hopes will help to speed the development of the mRNA-based Flash-CARTM program. Moreover, SLET’s ability to deliver mRNA to immune effector cells with pinpoint accuracy might pave the way for a new age of cancer immunotherapy.
This wide and possibly disruptive technology platform also has a variety of additional therapeutic and diagnostic uses. Furthermore, the company thinks that these new patent filings will provide them with strong international IP protection for this technology and its numerous uses.
Synthesis of Novel Cell Membrane Receptor Targets by AVCO – What’s going on?
On 7th October 2021, AVCO announced the co-creation of a unique cell-free in-silico method to help the company with medication development. The novel method demonstrates that difficult-to-study cell membrane proteins may be successfully produced in a cell-free environment.
The technology improves Avalon’s ability to design and manufacture novel membrane proteins. This is as receptors found on the surface of immune cells and cancer cells that are important for cell signaling.
New Cancer Immunotherapy – Will the results be beneficial?
On 4th August 2021, AVCO announced that a new collaboration between UPMC Hillman Cancer Center, the University of Pittsburgh, and Avalon GloboCare Corp. focuses on developing new cancer immunotherapy strategies and optimizing production processes so that these potent treatment options can reach cancer patients in days rather than weeks.
Many cancer patients benefit from cancer immunotherapy. This activates and educates the patient’s immune system to target and kill tumors while leaving healthy cells alone. Moreover, Chimeric antigen receptor (CAR) T-cell therapy modifies a patient’s own T cells to destroy cancer cells. Lastly, some individuals with leukemias, lymphomas, and, more recently, multiple myeloma have benefited from this method.
